Discontinued — last reported Q4 '23
Products & Services · Deferred revenues, noncurrent
Comirnaty — Deferred revenues, noncurrent
Pfizer Comirnaty — Deferred revenues, noncurrent decreased by 44.8% to $552M in Q4 2023 compared to the prior quarter. Year-over-year, this metric grew by 616.9%, from $77M to $552M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2021
Last reportedQ4 2023Feb 22, 2024
Rolls up toContract Liabilities
How to read this metric
An increase suggests long-term revenue stability and multi-year contractual commitments.
Detailed definition
The portion of deferred revenue related to the Comirnaty product line that is expected to be recognized as revenue beyon...
Peer comparison
Standard classification for long-term contract liabilities in pharmaceutical and technology sectors.
Metric ID:
pfe_segment_comirnaty_deferred_revenues_noncurrentHistorical Data
7 periods
| Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $264M | $249M | $77M | $34M | $28M | $1B | $552M |
| QoQ Change | — | -5.7% | -69.1% | -55.8% | -17.6% | >999% | -44.8% |
| YoY Change | — | — | -69.1% | — | — | — | +616.9% |
Range$28M – $1B
CAGR+63.5%
Avg YoY Growth+273.9%
Median YoY Growth+273.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's comirnaty — deferred revenues, noncurrent?
- Pfizer (PFE) reported comirnaty — deferred revenues, noncurrent of $552M in Q4 2023.
- How has Pfizer's comirnaty — deferred revenues, noncurrent changed year-over-year?
- Pfizer's comirnaty — deferred revenues, noncurrent increased by 616.9% year-over-year, from $77M to $552M.
- What does comirnaty — deferred revenues, noncurrent mean?
- Deferred revenue for Comirnaty that will be earned more than one year in the future.